To see all protocols that comply with the WHO Essential Medicine List 

Recommended tumour lysis sydrome prophylaxis based on tumour burden from clinical trials data.r 

Tumour Burden Prophylaxis

Blood Chemistry Monitoring**^
(Setting and frequency of assessments)

High

Any LN ≥ 10 cm OR

ALC ≥ 25 x 109/L AND

any LN ≥ 5 cm

1.5 to 2 L oral hydration* AND 150-200 mL/hr intravenous as tolerated

Allopurinol (starting 2 to 3 days prior to venetoclax)

Consider rasburicase if baseline uric acid is elevated

In hospital at first dose of 20 mg and 50 mg

  • Pre-dose, 4, 8, 12 and 24 hours

Outpatient at subsequent ramp-up doses

  • Pre-dose, 6 to 8 hours, 24 hours
Medium

Any LN 5 cm to < 10 cm OR

ALC ≥ 25 x 109/L

1.5 to 2 L oral hydration* AND consider additional intravenous 

Allopurinol (starting 2 to 3 days prior to venetoclax)

Outpatient 

  • Pre-dose, 6 to 8 hours, 24 hours at first dose of 20 mg and 50 mg 
  • Pre-dose at subsequent ramp-up doses 
  • Consider hospitalisation for patients with CrCl < 80 mL/min at first dose of 20 mg and 50 mg (and follow hospital monitoring above)
Low

All LN < 5 cm AND 

ALC < 25 x 109/L

1.5 to 2 L oral hydration*

Allopurinol (starting 2 to 3 days prior to venetoclax)

Outpatient

  • Pre-dose, 6 to 8 hours, 24 hours at first dose of 20 mg and 50 mg 
  • Pre-dose at subsequent ramp-up doses

ALC = absolute lymphocyte count; LN = lymph node
* administer intravenous hydration for patients who cannot tolerate oral hydration
** Monitor potassium, uric acid, phosphorous, calcium and creatinine; review in real time
^ For patients at risk of TLS, monitor blood chemistries at 6 to 8 hours and at 24 hours at each subsequent ramp-up dose

While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3514

21 Nov 2019